期刊文献+

Preconditioning of intravenous parecoxib attenuates focal cerebral ischemia/reperfusion injury in rats 被引量:9

Preconditioning of intravenous parecoxib attenuates focal cerebral ischemia/reperfusion injury in rats
原文传递
导出
摘要 Background Several studies suggest that cyclooxygenase-2 (COX-2) contributes to the delayed progression of ischemic brain damage. This study was designed to investigate whether COX-2 inhibition with parecoxib reduces focal cerebral ischemia/eperfusion injury in rats. Methods Ninety male Sprague-Dawley rats were randomly assigned to three groups: the sham group, ischemia/reperfusion (I/R) group and parecoxib group. The parecoxib group received 4 mg/kg of parecoxib intravenously via the vena dorsalis penis 15 minutes before ischemia and again at 12 hours after ischemia. The neurological deficit scores (NDSs) were evaluated at 24 and 72 hours after reperfusion. The rats then were euthanized. Brains were removed and processed for hematoxylin and eosin staining, Nissl staining, and measurements of high mobility group Box 1 protein (HMGB1) and tumor necrosis factor-α (TNF-α) levels. Infarct volume was assessed with 2,3,5-triphenyltetrazolium chloride (TTC) staining. Results The rats in the I/R group had lower NDSs (P 〈0.05), larger infarct volume (P 〈0.05), lower HMGB1 levels (P 〈0.05), and higher TNF-α levels (P 〈0.05) compared with those in the sham group. Parecoxib administration significantly improved NDSs, reduced infarct volume, and decreased HMGB1 and TNF-α levels (P 〈0.05). Conclusions Pretreatment with intravenous parecoxib was neuroprotective. Its effects may be associated with the attenuation of inflammatory reaction and the inhibition of inflammatory mediators. Background Several studies suggest that cyclooxygenase-2 (COX-2) contributes to the delayed progression of ischemic brain damage. This study was designed to investigate whether COX-2 inhibition with parecoxib reduces focal cerebral ischemia/eperfusion injury in rats. Methods Ninety male Sprague-Dawley rats were randomly assigned to three groups: the sham group, ischemia/reperfusion (I/R) group and parecoxib group. The parecoxib group received 4 mg/kg of parecoxib intravenously via the vena dorsalis penis 15 minutes before ischemia and again at 12 hours after ischemia. The neurological deficit scores (NDSs) were evaluated at 24 and 72 hours after reperfusion. The rats then were euthanized. Brains were removed and processed for hematoxylin and eosin staining, Nissl staining, and measurements of high mobility group Box 1 protein (HMGB1) and tumor necrosis factor-α (TNF-α) levels. Infarct volume was assessed with 2,3,5-triphenyltetrazolium chloride (TTC) staining. Results The rats in the I/R group had lower NDSs (P 〈0.05), larger infarct volume (P 〈0.05), lower HMGB1 levels (P 〈0.05), and higher TNF-α levels (P 〈0.05) compared with those in the sham group. Parecoxib administration significantly improved NDSs, reduced infarct volume, and decreased HMGB1 and TNF-α levels (P 〈0.05). Conclusions Pretreatment with intravenous parecoxib was neuroprotective. Its effects may be associated with the attenuation of inflammatory reaction and the inhibition of inflammatory mediators.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第13期2004-2008,共5页 中华医学杂志(英文版)
关键词 cerebral ischemia PARECOXIB neuropdotection INFLAMMATION cerebral ischemia parecoxib neuropdotection inflammation
  • 相关文献

参考文献23

  • 1Hurley SD, Olschowka JA, O'Banion MK. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 2002; 19: 1-15.
  • 2Gilgun-Sherki Y, Melamed E, Often D. Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Curr Pharm Des 2006; 12: 3509-3519.
  • 3Sasaki T, Nakagomi T, Kirino T. Tamura A, Noguchi M, Saito I, et al. Indomethacin ameliorates ischemic neuronal damagein the gerbil hippocampal CA1 sector. Stroke 1988; 19: 1399-1403.
  • 4Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, Stetler RA, et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 1998; 95: 10954-10959.
  • 5Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997; 17: 2746-2755.
  • 6Kelsen J, Kjaer K, Chen G Pedersen M, RChl L, Frckiaer J, et al. Parecoxib is neuroprotective in spontaneously hypertensive rats after transient middle cerebral artery occlusion: a divided treatment response? J Neuroinflammation 2006; 3:31.
  • 7Butovas S, Lukkarinen J, Virtanen T, Jolkkonen J, Sivenius J. Differential effect of the alpha2-adrenoceptor antagonist, atipamezole, in limb-placing task and skilled forepaw use following experimental stroke. Restor Neurol Neurosci 2001; 18: 143-151.
  • 8Yrjanheikki J, Koistinaho J, Kettunen M, Kauppinen RA, Appel K, Hall M, et al. Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. Brain Res 2005; 1052: 174-179.
  • 9Gerriets T, Li F, Silva MD, Meng X, Brevard M, Sotak CH, et al. The macrosphere model: evaluation of a new stroke model for permanent middle cerebral artery occlusion in rats. J Neurosci Methods 2003; 122:201-211.
  • 10Wang R, Ma WG, Gao GD, Mao QX, Zheng J, Sun LZ, et al. Fluoro Jade-C staining in the assessment of brain injury after deep hypothermia circulatory arrest. Brain Res 2011; 1372: 127-132.

同被引文献22

引证文献9

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部